Chemokines, chemokine receptors and the gastrointestinal system

Abstract

The biological properties of tumor cells are known to be regulated by a multitude of cytokines and growth factors, which include epidermal growth factor receptor agonists and members of the transforming growth factor β family. Furthermore, the recent explosion of research in the field of chemokine function as mediators of tumor progression has led to the possibility that these small, immunomodulatory proteins also play key roles in carcinogenesis and may, therefore, be potential targets for novel therapeutic approaches. In this review, we will summarize recently reported findings in chemokine biology with a focus on the gastrointestinal tract.

Key Words: Chemokine; Receptor; Signal transduction; Tumor progression; Targeted therapeutics; Digestive system; Cancer

Core tip: The chemokine network makes an attractive target for therapeutic intervention in many tumor types, including those of the gastrointestinal tract. However, we need to define more selective and specific targets, to minimize systemic side effects during treatment.

INTRODUCTION

Cancer development and progression in the gastrointestinal tract

Cancer is a disease in which normal cells acquire genetic and epigenetic abnormalities[1,2], leading to disorientation of conventional processes for the maintenance of normal cell physiology. These aberrant genetic and epigenetic modifications to the normal cell induce abnormal cell motility, proliferation, and survival, eventually enabling these cells to invade into adjacent tissues and even to migrate to regional or distant organs where they may grow continuously as metastatic lesions[3]. For many cancer patients, metastasis is generally the major cause of disease-related death[4,5]. Therefore, it is indispensable to elucidate the basic molecular mechanisms of tumor development to identify effective therapeutic targets, which can possibly reduce the side-effects of treatment, and define useful molecular markers for early detection and prediction of disease course. Especially, the newly emerged concept of personalized medicine may require in-depth assessment of potential therapeutic molecular target(s) in each individual case through analysis of signaling pathways and subsequent validation of treatment efficacy[6].

Numerous reports have identified molecules that play key roles in development of gastrointestinal cancer. Amongst these, which include growth factors and their receptors[7-9], signaling pathway components[10,11], transcription factors[12,13], matrix remodeling enzymes[14,15] and cytokines[16-18], a milestone finding by Müller et al[19] made chemokines one of the most intensively studied molecular targets to understand the mechanisms of organ-specific metastasis. The chemotactic cytokines or chemokines contribute to the tumor microenvironment by establishing a chemokine gradient, which is important for the process of chemoattraction and subsequent cell motility and infiltration for metastasis[20,21]. In this review, we will summarize the current status of chemokine-related studies in digestive tract cancer.

Recent progress has made it clear that the non-tumor cells, such as stromal fibroblasts and inflammatory cells present in the microenvironment, also play critical roles in establishing the metastatic phenotype of tumor cells[22,23]. Indeed, a role for inflammation in cancer progression is well-recognized, with many different cancer types having an inflammatory component[24]. Tumor cell infiltration is aided by the presence of tumor-associated macrophages (TAMs), dendritic cells and lymphocytes[25-28]. While TAMs are able to kill tumor cells, they also play an important role in enhancing tumor development by secreting matrix metalloproteinases (MMPs)[29,30], growth factors [interleukins (ILs), vascular endothelial growth factors (VEGFs)] and pro-angiogenic factors that support tumor cell growth, neovascularization, and tumor cell invasion through the stromal tissues[31].

Chemokines and signal transduction

Chemokines and chemokine receptors: In humans, the chemokine superfamily is comprised of more than 50 small secreted proteins. These molecules function as immune modulators, chemoattractants and as activators of lymphocytes. They are sub-divided into four major groups based on the relative position of conserved cysteine residues near to the N-terminus: CXC-, CC-, C-, and CX₃C-chemokines[32-34]. The CXC-chemokines can be further subdivided according to the presence or absence of a three amino acid motif immediately N-terminal to the first cysteine. Therefore, a glutamic acid-leucine-arginine (ELR) sequence defines the ELR⁺ CXC-chemokines, which generally function as activators and chemoattractants for neutrophils. In contrast, lymphocytes constitute the target cell type for most ELR^- CXC chemokines. The CC-chemokines play both chemoattractant and immunomodulatory roles. CCL5 attracts monocytes, eosinophils and memory T-cells, and is one of the human immunodeficiency virus (HIV)-suppressive factors secreted by CD8⁺ T-cells[35]. Similarly, CCL3 and the closely related CCL4 are also capable of inhibiting HIV infection of target cells, in addition to their pro-inflammatory and chemoattractant functions[35]. Furthermore, CC-chemokines are also reported to be involved in lymphocyte recirculation and homing to secondary organs (CCL21), as well as T-cell trafficking within the thymus (CCL19)[36-38].

While the major biological functions ascribed to chemokines regulate leukocyte trafficking and recruitment to inflammatory foci, chemokine receptors are also expressed on non-immune cells, and act as key modulators of the biological functions of other cell types. For example, CCL3 is a negative regulator of keratinocyte growth[39], while the CXC-chemokine ligand (CXCL) 5[40], CXCL8[41,42] and other ELR⁺ chemokines stimulate endothelial cell migration during angiogenesis[43].

To date, 19 chemokine receptors are known to be expressed in mammals[44]. Chemokines activate these specific G-protein-coupled receptors (GPCRs) on the surface of target cells. Chemokine receptors consist of an extracellular ligand binding domain, seven transmembrane spans, and an intracellular carboxyl terminus. The transmembrane domain consists of three intracellular domains and three hydrophobic extracellular domains. Variation of the amino-terminus sequence of these receptors defines the specificity for recognition of chemokine ligands, the binding of which results in phosphorylation of Ser/Thr residues in the intracellular domain and induction of f to the N-terminus of the receptor, specific signal transduction will be induced by the release of these heterotrimeric G-proteins (guanine nucleotide-binding proteins -G/G/G) that are bound to the intracellular carboxyl terminus. Each of these heterotrimeric G-proteins consists of several different subtypes[45]. Chemokine receptors are sub-divided into four types in relation to the class of ligand to which they bind: CXC-chemokine receptors (CXCR), which bind CXC-chemokines; CC-receptors (CCR), for CC-chemokines; and XC-receptors and CX₃C-receptors (CX₃CR) for XC- and CX₃C-chemokines, respectively. Among these receptors and ligands, there is promiscuous binding between several receptors and multiple chemokines (Table 1)[38].

Table 1 Ligand specificity of chemokine receptors implicated in gastrointestinal disease.

CC-chemokines		CXC-chemokines		CX3C-chemokine
Ligands	Receptors	Ligands	Receptors	Ligands	Receptors
CCL2	CCR2	CXCL1	CXCR2/CXCR1	CX3CL1	CX3CR1
CCL3	CCR1/CCR5	CXCL2	CXCR2
CCL4	CCR5	CXCL4L1	CXCR3
CCL5	CCR1/CCR3/CCR5	CXCL5	CXCR2
CCL7	CCR1/CCR2/CCR3	CXCL7	CXCR2
CCL8	CCR3/CCR5	CXCL8	CXCR1
CCL13	CCR2/CCR3	CXCL9	CXCR3
CCL19	CCR7	CXCL10	CXCR3
CCL20	CCR6	CXCL11	CXCR3
CCL21	CCR7	CXCL12	CXCR4/R7
CCL25	CCR9	CXCL14	Unknown
CCL27	CCR10	CXCL17	Unknown

CXCL: CXC chemokine ligand; CXCR: CXC-chemokine receptor; CCR: CC-receptor; CX₃CR: CX₃C-receptor.

Mechanisms of signal transduction: Binding of chemokines to their innate receptors can activate a number of intracellular signaling pathways that lead to cell proliferation and migration. Downstream mediators identified to date include the small GTPase Ras; extracellular signal-regulated kinases (ERK)[46,47]; phosphatidyl inositide-3-OH kinase (PI-3K)[47-49], and the other small GTPases Rho, Rac and Cdc42[50,51]; and some of these are active in pathways that regulate the actin cytoskeleton. For example, it was shown that migration of Jurkat cells in response to CXCL12 through CXCR4 is mediated by both Rac- and Rho-dependent mechanisms. While Rac is activated by G_i and G_βγ subunits, activation of RhoA occurs via G_α13 and leads to phosphorylation of myosin light chains[52]. Furthermore, CXCL8 (IL-8) signaling through CXCR1 has been reported to mediate migration of leukocytes in a β1-integrin-dependent manner which requires downstream activation of p38 and c-Jun N-terminal kinases[53]. The quality and the quantity of chemokine signaling is not controlled only by the expression volume of chemokine ligand/receptor but, also, by proteolytic processing of chemokine ligands. In this regard, MMPs are major modulators of chemokine signaling. For example, MMP9 can activate CXCL8 by processing its amino terminus, but it also abolishes the function of CXCL1 by cleaving it. Likewise, chemotactic activity of CCL7 is decreased by MMP2, and CXCL12 is decreased by multiple MMPs. However, numerous other proteases have also been documented to act upon chemokines and modulate their activity[54]. Furthermore, recent observations suggest more complexity in signal transduction mechanisms that are induced by heterodimerization of GPCRs[55]. As indicated above, chemokine and chemokine receptor interactions are complex and are connected to multiple combinations of effector proteins and divergent intracellular signaling pathways (Figure 1).

Figure 1 Chemokine-induced signal transduction pathways. Schematic representation of signaling pathways activated by binding of chemokine ligands to their seven transmembrane G-protein coupled receptors. MMPs: Matrix metalloproteinases; TFs: Transcription factors; RTK: Receptor tyrosine kinase; ERK: Extracellular signal-regulated kinase; MEK: Mitogen-activated protein/extracellular signal-regulated kinase kinase; PI-3K: Phosphatidyl inositide-3-OH kinase; MKK: Mitogen-activated protein kinase kinase; JNK: c-Jun N-terminal kinase; AKT: Protein kinase B.

Effects of chemokines on tumor cell proliferation

Many growth factors and cytokines act to control cell proliferation, either in a positive or a negative manner[56]. For example, epidermal growth factor (EGF) and related family members activate the EGF receptor (EGFR) and initiate divergent biochemical cascades that result in transcription of genes involved in cell cycle progression and other processes necessary for growth. In contrast, transforming growth factor-beta negatively regulates epithelial cell growth by inhibiting cell cycle transit. Signal transduction pathways regulated by these and other growth factors frequently become altered during tumorigenesis, resulting in deregulated cell growth. It has now become clear that deregulated function of multiple chemokines also contributes to enhanced tumor cell proliferation.

The ELR⁺ CXC-chemokines play important roles in melanoma cell growth[57,58]. CXCL1 has also been implicated in non-melanoma skin cancers, including tumors of neural origin and squamous cell carcinomas. Zhou et al[59] demonstrated that CXCL1 is highly expressed in anaplastic astrocytomas in vivo, and reported that this enhanced cell growth, motility, adhesion to extracellular matrix, and invasion in vitro, as well as enhanced aggressiveness in vivo. Constitutive expression of CXCL1 in squamous cell carcinomas results in formation of an autocrine growth loop through the CXCR2 receptor, while overexpression of CXCL1, CXCL2 and CXCR2 in esophageal cancer also enhances proliferation[60]. Furthermore, it was found that CXCL2 activates signal transduction through an ERK dependent pathway[61].

Transcriptional upregulation mediated through nuclear factor κB (NFκB)-dependent pathways has been reported to be largely responsible for the enhanced levels of CXCL1 in tumor cells. The tumor promoter okadaic acid, which inhibits protein phosphatases and results in hyperphosphorylation of proteins at serine and threonine residues, activates transcription through two response elements in the CXCL1 promoter, utilizing three distinct NFκB subunits (p65, p52 and c-Rel)[62]. Upregulation of NFκB by the upstream NFκB-inducing kinase is also an important mechanism by which CXCL1 is upregulated[63]. NFκB-dependent induction of CXCL1 is further regulated by poly (ADP-ribose) polymerase-1 (PARP-1). Inactive PARP-1 binds to the CXCL1 promoter and blocks transcription by excluding NFκB. However, activation of PARP-1 causes its promoter binding ability to be lost leading to NFκB upregulation of CXCL1. In melanoma cells, PARP-1 is highly expressed and active[64], and may be a major contributor to melanoma cell proliferation via chemokine-dependent mechanisms, together with constitutively expressed NFκB.

Chemokines in tumor cell migration, invasion and homing

In terms of cancer metastasis, chemokine-dependent mechanisms for targeting to specific secondary sites is now widely recognized after studies showed upregulation of CXCR4 and CCR7 in breast cancer cells and that activation of these receptors could induce actin polymerization, migration and invasion[19]. Importantly, ligands for these receptors were shown to be expressed in organs that represent the primary sites for breast cancer metastasis, strongly suggesting that ligand-receptor “homing” functions in vivo to target tumor cells to sites of secondary growth. Organ-specific metastasis has been reported for different tumor types, including breast[65], ovary[46] and epidermoid carcinomas[60]. Further, more than twenty tumor types have been documented to overexpress CXCR4[66]. Upregulation of CXCR4 expression in tumor cells through the action of VEGF also appears to be an important mechanism to further enhance invasiveness[67].

CXCR4/CXCL12 overexpression is associated with metastasis to lung, liver, lymph nodes and bone marrow. Rearrangement of the actin cytoskeleton and alteration in cell polarity are fundamental processes required for cell motility, regulated at least in some cases by CXCL12-CXCR4 pathways[68]. CXCL12-CXCR4 signaling may also contribute to tumor progression by upregulating protease expression. In prostate cancer cells, various MMPs were shown to be modulated by CXCL12[69]. However, these effects were not consistent for all cell lines examined, suggesting that cell-specific factors may influence the response to CXCL12. In glioma cells, CXCL12 induced expression of MMP15 but not gelatinases. RNA interference studies proved that glioma cell invasiveness in vitro, and tumor aggressiveness in vivo, is due to the upregulation of MMP15 by CXCL12[70]. Chemokine-receptor interactions in skin, as a frequent metastatic site of malignant melanoma, may be another example: CCL27 is highly expressed in skin and the CCR10 receptor for this ligand is frequently upregulated in melanoma cells[71,72].

Furthermore, mounting evidence points to cancer-associated stromal fibroblasts playing important roles in modulating tumor cell behaviour[73,74]. As p53 mutation or loss has been shown to occur in stromal cells[75,76], this may upregulate CXCL12 and enhance proliferation and motility[77].

Chemokines and tumor cell survival

The majority of metastatic tumor cells fail to colonize secondary lesions successfully, most likely due to induction of programmed cell death[78]. For metastasized lesions to grow, enhancement of growth factors as well as positive molecular interactions with surrounding cells in the lymph node or other organs are indispensable. For example, EGFR signaling can activate survival pathways regulated by protein kinase B (AKT)[79]. However, despite the presence of available growth factors, tumor growth at the secondary lesion may still be uncertain: it may also require other factors and/or pathways in order for cells to survive and proliferate. Studies have also shown that resistance to cell death induced by loss of attachment to the extracellular matrix (anoikis) is an important element at least for certain tumors[80]. Interestingly, some chemokine-receptor combinations, such as CXCL5-CXCR2[48] and CCL19/21-CCR7[81], can activate PI-3K and AKT, key regulators of cell survival. Thus, interaction of chemokines with their receptors could play roles in multiple and complex biological processes that are important for successful survival in metastasized locations. For example, CCL2 is well known for regulating cell migration and is a key mediator of breast cancer cell migration[82]. Also using breast cancer cell lines, Fang et al[83] demonstrated enhanced cell migration and survival along with increased phosphorylation of Smad3 and mitogen-activated protein kinases (MAPKs) in response to CCL2 and, moreover, they found that levels of the innate receptor CCR2 were elevated in breast cancers, accompanied with CCL2 expression. These investigators also suggested that MAPK and Smad3 signaling function as an independent/alternative mechanism for cell survival. Furthermore, they showed that CCL2-induced Smad3 signaling through MAPKs regulates expression and activity of Rho GTPase, thereby facilitating breast cancer cell motility and survival. Therefore, beyond well-described canonical chemokine ligand/receptor signaling, new molecules may need to be considered as critical players in chemokine signaling in cancer. The CXCL12-CXCR4 signaling pathway has been shown to be important for the survival of leukemic B cells in chronic lymphocytic leukemia (CLL) through activation of AKT and ERK1/2[84,85]. Moreover, O’Hayre et al[86] recently identified additional molecular targets and novel phosphoproteins as possible mechanisms for cell survival in CLL. Amongst these is programmed cell death factor 4, found in all CLL cells examined, and also heat shock protein 27, which mediates anti-apoptotic signaling and has previously been linked to chemotherapeutic resistance, which was detected in a subpopulation of CCL patients. If the roles of these cell-survival-related proteins are supported by further future studies, it may be worth considering identifying these and other phosphoproteins whose functions are modified by certain chemokines in specific pathological conditions, such as cancer and/or inflammation in gastrointestinal disease.

Chemokines and angiogenesis

Development of microvessels is an another critical event that enables oxygen delivery and nurtures tumor cell survival at both primary and secondary sites[87]. Recently, intensive studies in normal angiogenic development using mouse model systems have revealed the importance of the angiogenic chemokine CXCL12 for the organized development of vessel branching along with neural development (https://intramural.nhlbi.nih.gov/labs/ldbsn/pages/publications.aspx). Furthermore, Komatsu et al[88] reported the importance of the small-G protein R-Ras for the development of abnormal collateral capillary systems which may play critical roles in the survival of localized tumors by supporting nutrient and oxygen delivery^,[89]. Nonetheless, it remains unclear how the tumor cells, which express chemokine receptors, respond to chemokines released from these pathological vessels, which are inherently “leaky”. Several different chemokines are known to be pro-angiogenic, notably CXCL5 and CXCL8. Koch et al[90] clearly demonstrated that CXCL8 could induce neovascularization in a rabbit corneal pocket assay. Furthermore, they also showed that the angiogenic activity present in conditioned media derived from macrophages or monocytes from rheumatoid synovial tissues was dependent upon CXCL8. Indeed, macrophages have been reported to induce malignant progression in a breast cancer model by initiating the angiogenic switch[91]. Additionally, CXCL8-CXCR2 signaling facilitates migration and proliferation of endothelial cells[92], and the AKT pathway is important for GPCR-dependent angiogenesis[93] following CXCR1 and CXCR2 activation[49,81]. Also, the human herpesvirus-8, an etiological agent of the highly vascular Kaposi’s sarcoma, induces expression of CXCL8[94], providing further evidence for chemokine involvement in tumorigenesis[95].

Notably, in contrast to the ELR⁺ chemokines discussed above, most ELR^- chemokines have anti-angiogenic or angiostatic activity[96]. Among these, CXCL9, CXCL10 and CXCL11 are inducible by other cytokines, including members of the IL family and interferons. The angiostatic response of these cytokine-inducible chemokines is mediated through the CXCR3 receptor, found on the surface of endothelial cells[97]. Specifically, an alternatively spliced variant of the receptor - CXCR3B - has been shown to mediate this activity[98]. In addition to inhibiting endothelial cell migration, these chemokines also block proliferation. A further critical review focused on the development of tumor angiogenesis is available[99].

CHEMOKINES IN DIGESTIVE SYSTEMS/DEVELOPMENT AND PROGRESSION

Compared to normal cells, many cancer cells overexpress chemokine and chemokine receptors. Ligation of overexpressed chemokine receptors on tumor cells and the specific chemokines released from target organs seem to be critical regulators of metastasis[19,100]. As outlined above, chemokines and their receptors play various important roles in the regulation of invasion, metastasis and dissemination of cancer cells. Here we review chemokine/chemokine receptor interactions, specifically in digestive organs.

Oral cavity

In the head and neck region, which includes oral cavity, pharynx, larynx, nasal cavity and paranasal sinuses, the head and neck squamous cell carcinoma (HNSCC) accounts for more than 90% of malignant neoplasms[101]. Despite intensive efforts, survival rates have shown limited improvement over the decades. When primary tumor location is taken into account, the outcome can be even worse, with advanced hypopharyngeal tumors having a 4% five-year survival[102]. Metastasis of HNSCC is generally via the lymphatic system to loco-regional sites. Recently, several different chemokines were shown to be highly expressed in HNSCC derived cell lines and patient tumor samples. For example, in a series of 94 HNSCCs, CXCL1 was found to be overexpressed in around 40% of lesions[103]. Measurement of microvessel density (MVD) in HNSCCs revealed a correlation between CXCL1 expression and angiogenic activity, as well as with nodal metastasis and infiltration of leukocytes. CXCL8 has long been recognized to participate in autocrine (and possibly paracrine) regulation of HNSCC proliferation[60]. Recent studies using global gene expression profiling of primary and synchronous metastatic HNSCC further support previous reports of CXCL8 upregulation[104]. Along with this observation, Chen et al[105] reported that hydrogen sulfide produced by Porphyromonas gingivalis bacteria in the oral cavity induced expression of CXCL8 in gingival and oral epithelial cells. Potentially, this may provide a link between tumor development and the induction of inflammation in periodontal disease, which is associated with persistent bacterial infection, and similar results to this study have also been reported[106].

In addition to CXCL8, another ELR⁺ angiogenic chemokine, CXCL5, is highly expressed in some HNSCCs. Data suggest that CXCL5 enhances tumor development by stimulating proliferation, cell motility and invasion[107] as knockdown of CXCL5 by siRNA completely inhibited tumorigenicity in a mouse xenograft model.

Furthermore, Delilbasi et al[108] reported upregulated CXCR4 expression in squamous carcinomas of the tongue by an immunohistochemical method. Of interest, their experiment exhibited no difference in expression between primary tumors of early and more advanced stage, although invading cells and those which had metastasized to lymph nodes exhibited higher CXCR4 expression, suggesting in vivo selection for this phenotype with malignant progression. Clatot et al[109] also studied the possible correlation of CXCL12/CXCR4 expression and tumor recurrence and survival in HNSCC patients. They found no meaningful correlation between CXCR4 expression and either recurrence or survival, but a significant difference in CXCL12 expression. Further prospective studies are required to clarify this.

The loss of CCR6 expression in metastatic lesions with concomitant elevation of CCR7 in some HNSCCs was also documented[110]. CCL19 and CCL21, ligands for CCR7, induced migration of metastatic cells in vitro, whereas primary tumor cells responded to the CCR6 ligand, CCL20. Together, these data suggest that CCR7 upregulation might play a role in targeting tumor cells to sites of secondary growth in vivo, by facilitating entry into the lymphatic system and migration to regional lymph nodes. CCR7 signal transduction was also shown to activate cellular invasion and pro-survival pathways by PI-3K and PLCγ-dependent, but EGFR-independent, mechanisms[111].

Esophagus

In the esophagus, several cytokines and chemokines are reported as possible mediators of gastroesophageal reflux, esophagitis, pre-cancerous change (typically Barrett’s esophagus) and adenocarcinoma[112]. Amongst these, CXCL8 is reported as a molecular marker indicative of response to therapeutic procedures. For example, Oh et al[113] compared the expression level of CXCL8 between pre- and postoperation of Nissen fundoplication in reflux esophagitis. They found that CXCL8 expression was significantly reduced postoperatively, as measured by quantitative real-time polymerase chain reaction (qRT-PCR). These authors also reported that CXCL8 expression was higher in patients with reflux compared to those without reflux. Furthermore, they found that patients with the highest CXCL8 expression were those with Barrett’s dysplasia and adenocarcinoma. Chemokines and several other cytokines, such as ILs, CXCL8, and VEGFs were found to be upregulated in cancer-related cachexia, although the underlying mechanism is not understood[114]. Moreover, chemokine expression in tumors is complicated. Verbeke et al[115] screened 51 patients operated on for colon adenocarcinoma, esophageal adenocarcinoma, or esophageal squamous cell carcinoma (SCC) by immunohistochemical staining to examine the expression of CXCL4L1, CXCL8, CXCL10, CXCL12, and VEGF. According to their study, the angiostatic chemokine CXCL4L1 was strongly expressed in colorectal cancer, while there was weaker expression in esophageal cancer. CXCL12 staining was almost negative in esophageal SCC, while stronger staining was observed in adenocarcinoma of the esophagus and colon. VEGF was moderately-to-strongly positive in all 3 types of cancer, but relatively weaker in esophageal adenocarcinoma. Interestingly, not only was the expression of the angiogenic chemokines CXCL8 and CXCL12 heterogeneous in the samples, but so was the expression of the angiostatic chemokines CXCL10 and CXCL4L1. Based on these results, the roles of chemokines are likely complex in these tumors[115]. Recently, in vitro and in vivo studies using AMD3100, a pharmacological CXCR4 inhibitor, and the human HER2 inhibitor, trastuzumab, have indicated CXCR4 to be a positive regulator of human epidermal growth factor receptor 2 (HER2) expression in esophageal cancer. In this study, the authors also suggested a possible complex relationship between HER2 and CXCR4 in tumor development and metastasis[116]. These observations indicate further the involvement of multiple chemokines in molecular events that underpin different stages of cancer development.

Stomach

In gastric cancer treatment, detection at an early stage of tumor development is still the most effective curable approach. Amongst different types of gastric cancer, peritoneal dissemination is one of the most incurable conditions and no radical and effective treatment is available to date. Hashimoto et al[117] showed that the CXCL12/CXCR4 axis is important in peritoneal dissemination of gastric cancer cells. They found that CXCL12 ligation to CXCR4 on the cancer cell surface strongly and rapidly activates AKT-mammalian target of rapamycin signaling and co-activates production of other metastatic mediators, such as MMPs[117,118]. Graziosi et al[119] also suggested possible involvement of the p38 MAPK pathway in the development of peritoneal dissemination. Using an in vivo mouse system and administering p38 MAPK inhibitors ML3403 or SB203580, they observed decreased tumorigenesis. Microarray studies using these cancer cells identified several downregulated genes, such as CXCR4, fms-related tyrosine kinase 4, non-receptor spleen tyrosine kinase and collagen α2(IV). Interestingly, p38 MAPK inhibitors induced significant downregulation of multidrug resistance-1 gene expression, a well-defined marker of resistance to chemotherapy, which possibly induced susceptibility to the cisplatin treatment in this model[119]. In a separate study, Zhi et al[120] examined the expression of CXCL12 in normal gastric tissue, gastric cancer cell lines, 35 primary gastric carcinomas and corresponding normal gastric tissues. They found that CXCL12 was downregulated in gastric cancer cell lines and patient samples of primary gastric carcinomas compared to normal samples. They provided evidence to show that CXCL12 expression was inversely associated with lymph node metastasis and histological grade. They concluded the possible cause of this downregulation of CXCL12 expression to be hypermethylation of the CXCL12 promoter, as treatment of highly metastatic cancer cell lines with a demethylating agent impaired its invasive phenotype[120]. One possible explanation for this reduction in CXCL12 might be to permit CXCR4-expressing gastric cancer cells to sense a CXCL12 gradient from target lymph nodes or other organs, which would otherwise be masked by CXCL12 expressed by the cancer cells. Together, these reports suggest that the peritoneal dissemination may be induced by the dissemination of CXCR4-expressing gastric cancer cells directed into the peritoneal area, which expresses high levels of CXCL12. Therefore, blocking molecular targets such as AKT and/or CXCR4 could be possible treatment strategies to prevent the activation of signaling events induced by CXCR4 ligation mediated by CXCL12 on the cancer cell surface. Moreover, preventing peritoneal dissemination itself might be possible by developing specific inhibitors that prevent binding between CXCR4 and its ligand. In this regard, Manu et al[121] investigated plumbagin, which is a CXCR4 expression inhibitor, and it was widely effective in downregulating CXCR4 expression in cancer cell lines irrespective of the tissue of origin. The suggested mechanism of CXCR4 downregulation by plumbagin is through inhibition of NFκB. However, regulation of CXCR4 expression in cancer cells may not be so straightforward as initially expected. Bao et al[122] found that HER2, which is frequently overexpressed in gastric cancer, interacts with CD44 and induces CXCR4 expression by blocking expression of microRNA-139. Additionally, EGF signaling may play an important synergistic role in concert with the CXL12/CXCR4 axis in gastric cancer metastasis, as Yasumoto et al[123] found that the EGFR ligands amphiregulin and heparin-binding EGF (HB-EGF)-like growth factor, as well as CXCL12, are highly expressed in malignant ascites. Their work showed that HB-EGF and CXCL12 together enhanced tumor necrosis factor α-converting enzyme-dependent amphiregulin shedding from human gastric carcinoma (NUGC4) cells, which can promote proliferation of NUGC4 cells in animal models. These experiments strongly imply the possibility that several cancer signaling pathways besides the CXCL12/CXCR4 axis are important for development of gastric cancer metastasis.

When they screened 40 gastric cancer patient samples, Zhao et al[124] found that CXCR4 mRNA levels were significantly higher in cases with lymph node metastasis than those without; they also found that the CXCR4 protein level was correlated with poorly differentiated lesions, more advanced tumor stage and lymph node metastasis. Further, they reported higher CXCL12 mRNA in lymph nodes in patients with metastatic gastric cancer. Ingold et al[125] used qRT-PCR to screen CXCL12/CXCR4 mRNA levels in 37 gastric carcinomas, and as well as screening protein levels in 347 gastric carcinomas and 61 matching lymph node metastases using tissue microarrays. They concluded that tumors expressing both CXCL12 in tumor cells and CXCR4 in adjacent microvessels showed a strong correlation with local tumor development and Union for International Cancer Control stages.

Another interesting study recently reported by Xu et al[126] describes the possible activation of lymphangiogenesis pathways in gastric cancer by CXCL1 secretion. A technique was established in an animal model for recovery of lymphatic endothelial cells (LECs) from afferent lymph vessels of sentinel lymph nodes, and the gene expression profile between normal LECs and LECs with lymph node metastasis was compared using microarray analysis. They found that CXCL1 stimulated LEC migration and tube formation through FAK-ERK1/2-RhoA activation and reorganization of F-actin. Importantly, it is well known that CXCR2 expression, which is a CXCL1 receptor, is positively correlated with tumor, node, and metastasis (TNM) stage and lymphatic vessel density[127-130]. Thus, this study may strongly imply a role for CXCL1 in metastasis mediated through effects on LECs. CXCL8 has also been well studied in gastric cancer development. Using the gastric cancer cell line SCG-7901, Ju et al[131] found that CXCL8 can enhance several tumor parameters, such as adhesion to endothelial cells, migration, and invasion. The expression of MMP9, intercellular adhesion molecule (ICAM)-1 and E-cadherin was upregulated in a dose-dependent manner. However, CXCL8 did not affect the proliferation of SCG-7901 cells under these conditions. Several groups have studied polymorphism of the CXCL8 251 allele. Wang et al[132] reported the CXCL8 251 allele AA genotype as a risk factor for gastric cancer in Asian groups but not in Caucasian or Mexicans. Furthermore, statistical analysis revealed that the TA and AA polymorphism is significantly associated with the diffuse type of gastric cancer, and the AA genotype was found to be a risk factor for gastric cardia cancer. Song et al[133] reported screening results of this allele in Helicobacter pylori (H. pylori)-infected Korean populations. They found a significant correlation between MMP9 and disease progression in the AA and AT genotype. Angiopoietin-1, which plays an important role in vascular development, showed upregulation, but not VEGF expression or disease progression in the AA genotype. They predicted that the CXCL8 251 AA genotype may be associated with angiogenesis in gastric carcinogenesis in the H. pylori-infected population. Vinagre et al[134] reported that interaction between CXCL8 251 (AA and AT) allele mutation carriers and the infection of H. pylori strain [phosphoinositide PI4, 5P(2) binding protein (s1m1) cytotoxin-associated gene A product (cagA) positive] may have higher risk for development of gastric adenocarcinoma. In addition, Schneider et al[135] pointed out the complexity and difficulty in selecting in vitro epithelial study models to understand the molecular mechanisms of H. pylori infection. Moreover, a meta-analysis carried out by Liu et al[135] indicated that the variable results reported by many different studies can be affected by differences of histological type, tumor location, H. pylori infection, ethnicity and geographic location[136]. Another CXC chemokine, CXCL5, was also reported recently to be a potential molecular marker for cancer development, especially for late stage gastric cancer[137]. However, it is not yet confirmed if this observation is a consequence of secondary change as a result of gastric cancer progression, or whether it is one of the primary molecular events leading to tumor development. As CXCL5 is linked to tumor development in other organs[77,107,138], further confirmation is needed through the use of in vitro and in vivo model systems in the future. Yanagie et al[139] performed a comparative analysis of differential gene expression related to chemokines/chemokine receptors and cytokines in established gastric cancer cell lines using a cDNA microarray approach. They found that CC-chemokines CCL2, 5, 21 and CXC-chemokines CXCL1, 7, 8, 12, 14 and chemokine receptor CCR6 were upregulated, while CCL3 and CCL25 were downregulated. These chemokines and their receptors may be potential candidates for cancer diagnosis and/or treatment.

Collectively, in gastric cancer development and metastasis, multiple chemokines likely play important roles. Further studies are required to elucidate the many functional roles of these chemokines, especially in synergistic regulation of the signaling pathways that control development of gastric cancers. Another detailed review on the role of chemokines in esophageal and gastric cancer is available[140].

Liver

The liver is one of the major metastatic targets of colon cancer and this attributes directly to patient mortality. Many molecules have been proposed as being responsible for the development of hepatic metastases, and accumulated data suggest there are several important signaling pathways involved in the development of both primary and metastatic liver cancer. Among them, the CXCL12-CXCR4, CX3CL1-CX₃CR1,and the CCL20-CCR6 axes have received much attention[141].

CXCR4 has been found to be a prognostic marker in various types of cancer as it plays an important role in normal stem cell homing. Cancer stem cells also express CXCR4, which implies that this axis may control the trafficking and metastasis of these cells to organs that express CXCL12, and the liver is one of these[142]. Recently, Li et al[143] reported that the expression of CXCR4 was higher in portal vein tumor thrombus tissue than hepatocellular carcinoma (HCC), and lentivirus-mediated siRNA knockdown of CXCR4 was shown to impair the potential invasiveness of tumor thrombus cells significantly. By screening tissues from 42 HCC patients, including tumor and adjacent regions, and comparing to tissues from cancer-free individuals, Liu et al[128] found that CXCR2 mRNA was significantly higher in HCC than in adjacent or normal liver tissues. Interestingly, TNM staging was not correlated to the level of CXCR2 mRNA but the protein level was relevant to staging, as protein was markedly higher in lesions classified as Stage III/IV. CXCR2 mRNA and protein levels were correlated with intrahepatic metastasis, portal cancer embolus, and low differentiation. Other studies recently reported a possible therapeutic use of CCL2 for prevention of HCC metastasis. In a model of HCC, coupling adenovirus-based CCL2 and the thymidine kinase/ganciclovir expression was shown to prevent intrahepatic metastasis in vivo. This combination was also shown to induce an innate immune response involving monocytes/macrophages and NK cells, leading to prolongation of anti-metastatic effects[144-146]. CCL2 was also identified by Chen et al[147] as a potential target for development of future HCC treatment. Using the recombinant foot-and-mouth disease virus capsid protein VP1 (rVP1), they were able to induce apoptosis of HCC cell lines through deactivation of the AKT pathway and stimulation of caspase cascades via Bax. Furthermore, rVP1 downregulated the expression of CCL2 in an AKT-dependent manner, which can support the survival and migration of HCC tumor cell lines[147]. CXCR7, a CXCL12 receptor, has also been reported to be upregulated in HCC[148]. In another study, shRNA knockdown of CXCR7 expression was found to inhibit many facets of tumor development, such as cell invasion, adhesion, VEGF secretion, endothelial tube formation and tumor growth, although it did not affect metastasis in vivo[149]. CXCR4, an alternative receptor to CXCR7 for CXCL12, is known to play important roles in liver metastasis. CXCL12 is expressed by endothelial cells and likely by Kupffer cells lining the liver sinusoids. The binding of CXCL12 to CXCR4 activates Rho, Rac and Cdc42, enabling tumor cell extravasation without affecting cell adhesion[150].

In addition to direct roles in cancer development, chemokines make important contributions to chronic inflammatory diseases such as chronic hepatitis, which can be a possible precancerous condition. In chronic hepatitis, regulation of lymphocyte motility is controlled by several independent biochemical pathways. However, these signaling events are not well elucidated despite well-documented observations of lymphocyte recruitment to tissues via endothelium. Holt et al[151] suggested that activated human liver myofibroblasts (aLMF) affect the migration and accumulation of lymphocytes within the inflamed liver. Also, when cultured in vitro, aLMF from inflamed human livers and hepatic stellate cells from non-inflamed livers secrete a distinct profile of cytokines and chemokines. The aLMF-conditioned media had chemotactic activity for lymphocytes, which was partially inhibited by pertussis toxin, implying a requirement for GPCR signaling. Additionally, contribution of GPCR-independent lymphocyte chemotaxis by IL-6, hepatocyte growth factor, and VEGF was also reported[151].

Pancreas

As a multitude of studies expand our knowledge of pancreatic disease, the important role of chemokines in the development of pancreatic cancer is becoming evident. CCL20 is well known for its expression in various human cancers[152-155]. In pancreatic adenocarcinoma (PAC) patients, CCL20 mRNA and protein expression was found to be significantly associated with advanced T-stage[154]. It is interesting that CCR6, a canonical CCL20 receptor, is upregulated in chronic pancreatitis, pancreatic cystadenoma and pancreatic carcinoma compared to controls[154]. It has also been reported that, in metastatic pancreatic carcinoma, expression of the angiogenic chemokines CXCL5 and CXCL8 is highly elevated compared to pancreatic cystadenoma or chronic pancreatitis[138]. This observation suggests a potential contribution of these chemokines to the development of metastatic pancreatic cancer. Furthermore, another report suggests that CXCL5 may be a possible prognostic biomarker for pancreatic cancer. Li et al[156] reported that overexpression of CXCL5 is correlated with poorer tumor differentiation, advanced clinical stage, and shorter patient survival. These authors also performed xenograft assays in nude mice, in which they used shRNA downregulation of CXCL5 or antibody-mediated neutralization of CXCR2 and showed attenuation of pancreatic tumor cell growth. They also demonstrated that CXCL5 derived angiogenesis development was ERK, AKT and signal transducer and activator of transcription mediated signaling pathways[156]. Moreover, in a clinical study that analyzed 52 PACs and 52 pancreatic neuroendocrine tumors, Hussain et al[157] found that expression of CXCL8 and its receptors CXCR1/2 were significantly upregulated compared to normal pancreatic tissues, a finding confirmed by immunohistochemistry and qRT-PCR. This may suggest the existence of autocrine and/or paracrine loops that contribute to the development of these tumors. As in other organs, many reports have suggested the importance of the CXCL12-CXCR4 axis in the development of pancreatic cancers. Cui et al[158] compared expression of CXCL12 and CXCR4 between tumor and surrounding tissues. In tumor tissues, CXCL12 expression was significantly lower than that found in paracancerous tissues, normal pancreas, or lymph nodes. In contrast, CXCR4 expression in cancerous tissues was significantly higher than that in normal tissue. Furthermore, expression patterns of the CXCL12/CXCR4 and clinicopathological status showed a strong correlation, including lymph node metastasis. Additionally, CXCL12 expression was significantly associated with MVD but not with microlymphatic vessel density, while CXCR4 expression showed the opposite relationship[158]. These observations imply a significant role for CXCL12/CXCR4 signaling in the development and progression of metastatic pancreatic cancer. Also, in another study, samples from 249 PAC patients were screened by immunohistochemistry and tissue microarray for expression of innate CXCL12 receptors CXCR4 and CXCR7. Expression of CXCR7 was found to be associated with tumor grade, inversely associated with tumor size, and possibly associated with tumor progression and differentiation[159]. Interestingly, though, no significant correlation was found between CXCR4 expression and clinicopathological parameters, which may seem to be inconsistent with previous reports[158]. However, this may be a manifestation of different mechanisms of pathogenesis. Together with these observations, data from many studies suggest CXCL12-CXCR4 signaling may be a rational therapeutic target to prevent the development and metastasis of pancreatic tumors[160,161]. For example, the activation of this axis can be attenuated by suppressing NFκB activity[162]. In pancreatic cancer, CX₃CL1 and its cognate receptor CX₃CR1, is another possible ligand-receptor combination associated with the pathogenesis of pancreatic cancer. Marchesi et al[163,164] reported involvement of CX₃CR1 in perineural invasion and dissemination of neoplastic cells along intra- and extra-pancreatic nerves. Use of CX3CR1 as a possible therapeutic candidate is discussed in detail elsewhere[165]. Pancreatic cancer is one of the most aggressive and intractable malignancies amongst all cancers[166]. Therefore, finding molecular markers to facilitate accurate diagnosis at early stages of disease is an urgent need. From the evidence available, several chemokine-receptor pairs may be good candidates. A combination of several markers, together with these chemokines, may be promising diagnostic tools, such as CXCL17-ICAM2[167] and a classical molecular marker for pancreatic cancer, carbohydrate antigen 19-9, together with CXCL7[168].

Small and large intestine

Inflammatory bowel disease (IBD) is a chronic inflammatory condition of the colon and small intestine. It is now considered that chemokine-mediated chronic inflammation is a direct cause of colitis-associated cancer (CAC). However, the underlying mechanism of CAC is complex and not well elucidated. CC-chemokines and their receptors have long been recognized as key players in tumor promotion and progression during the course of chronic colitis. In several reports, expression of CC-chemokines, including CCL2, is highly upregulated in the colonic mucosa of IBD patients, as well as in the azoxymethane and dextran sulfate sodium experimental colitis model system[169]. Observations in the D6 receptor knockout mouse provide another important example of the role of chemokines in IBD. D6 is a silent receptor known to bind to a wide array of pro-inflammatory chemokines promiscuously, including CCL2, 5, 8, 7, and 13 in humans. Compared to wild type mice, D6 knockout mice were found to be more susceptible to chemically-induced colitis and failed to recover from the colitis. This may be due to the lack of the D6 receptor, which usually sequesters overexpressed chemokines, failing to stop the development of symptoms[170], and D6 plays a similar role in preventing liver injury[171]. Consistent with a suppressor role for D6, lymphatic vessels expressing D6 were demonstrated in epithelium and connective tissue of both small and large intestine[172]. Using a CCR2 knockout mouse or a CCL2 antagonist, Popivanova et al[173] showed that CCL2 is a crucial mediator of colon cancer development, as mice lacking CCL2 had reduced intracolonic macrophage infiltration and COX-2 expression, attenuated neovascularization, and reduced numbers and size of colon tumors.

B-lymphocytes collected from patients with Crohn’s disease (CD) express toll-like receptor 2 (TLR2) at the cell surface and secrete high levels of CXCL8, and the clinical disease course is well correlated with CXCL8 expression[174]. In contrast, ulcerative colitis (UC) patients also express TLR2, but do not secrete CXCL8 in large amounts. However, CXCL8 is inducible in UC by stimulating TLR2 and its clinical activity correlates inversely with levels of circulating TLR2-positive B cells, converse to CD[174]. In a model of experimental colitis, it was shown that infection with Bacillus polyfermenticus (B. polyfermenticus) affects the biological responses of human intestinal microvascular endothelial cells, including cell migration, tube formation, and permeability through an NFκB/CXCL8 signaling axis[175]. Interestingly, this study also reported that B. polyfermenticus can accelerate the healing process of colitis by stimulating mucosal angiogenesis. Lopez et al[176] found that Lactobacillus rhamnosus GG (LGG), a probiotic, can downregulate the flagellin-induced expression of CXCL8. Although the biological mechanisms of LGG in the maintenance of intestinal homeostasis are largely unknown, it is proposed that LGG may modulate induction of CXCL8 by tumor necrosis factor-α (TNF-α) in the intestinal epithelium[176,177]. In colorectal adenocarcinoma cells HCT-116 and HCT-8, immunohistochemistry revealed that diverse stimuli can upregulate CXCL8 expression[115], with upregulation of CXCL4L1 and synergistic CXCL8 and CXCL10 induction in carcinoma cells by IL-1 and TNF-α or immunoreactive fibronectin. In addition, full-length and N-terminally truncated (more active) CXCL8 was identified in HT-29 colorectal adenocarcinoma cells, as well as strong expression of CXCL4L1 and CXCL12 in patient samples[115]. Moreover, ERK2 and PI-3K/AKT have been identified as candidate pathways for induction of CXCL8 expression in HCT-15 colon cancer cells and MKN-45 gastric adenocarcinoma cells[178].

Arijs et al[179] reported that, in inflamed colonic IBD mucosa, many leukocyte/endothelial cell adhesion molecules (CAMs) and chemokines/chemokine receptors are upregulated, while E-cadherin gene expression was downregulated. Microarray analysis revealed that infliximab (an anti-TNF-α antibody) restores colonic gene expression of endothelial CAMs and most chemokines/chemokine receptors to normal levels of expression, with only CCL20 and CXCL1/2 expression remaining elevated after treatment. In addition to the previously identified 47 integrin-MADCAM1 axis, this study revealed a number of interesting targets for anti-adhesion therapy, including PECAM1, CXCL8, and CCL20, suggesting that anti-TNF-α therapy may work, at least in part, by downregulating certain CAMs[179]. Upregulation of CXCL1, CXCR1 and CXCR2 was reported by Oladipo et al[180] in tumor epithelium compared to normal adjacent tissue collected from patients with stage II and III CRC. In their analysis, no overall association between CXCL1, CXCR1 or CXCR2 expression and prognostic endpoints was found, although survival analysis demonstrated an inverse association between CXCL1 and recurrence-free survival in stage III patients. Interestingly, CXCL8 positivity in the tumor infiltrate correlated with earlier disease stage and improved relapse-free survival in multivariate Cox regression analysis[180]. Schroepf et al[181] screened samples collected from 501 German patients with IBD (336 CD, 165 UC) including 258 children and 243 adults as well as 231 controls. They found CXCR3 pathway-related genes to be significantly overexpressed in inflamed colonic tissue of pediatric CD and UC patients. CXCL9, 10, and 11 are 3 innate ligands for CXCR3, and this study found a correlation between polymorphism in CXCL9 and pediatric CD, while carriers of the hetero- and homozygous genotype variants of CXCL11 rs6817952 were at increased risk for UC in all age groups. Thus, blockade of CXCR3 could be a possible therapeutic avenue in the future[181]. In a study using HT-29 colon cancer cells, Lee et al[182] reported multiple regulatory roles of IL-17 on chemokine expression. Their results indicated a positive effect of IL-17 on chemokines that recruit neutrophils (CXCL8 and CXCL1) and Th17 cells (CCL20). Contrary to this, IL-17 represses expression of CXCL10, CXCL11, and CCL5, three chemokines that selectively recruit Th1 lymphocytes.

Collectively, these findings suggest that synergistic targeting of critical proteins such as chemokines and their receptors may lead to improved treatment outcomes for inflammatory bowel disease and cancer. Table 2 is attached as a summary of published studies related to chemokine/chemokine receptors and gastrointestinal diseases according to their description in this review.

Table 2 Chemokines/chemokine receptors in this table appear sequentially according to their description in this review.

Organ	Chemokines and receptors	Possible role/observed phenomenon
Oral cavity	CXCL1	Angiogenic activity[103]
	CXCL8	Proliferation, metastasis, tumor development and the induction of inflammation in periodontal disease[60,104-106]
	CXCL5	Proliferation, cell motility and invasion[107]
	CXCR4	Enhancement of invasiveness[108]
	CXCL12	Upregulation in metastasis[109]
	CCR6, CCR7	Involvement in metastatic activity[110]
	CCR7	Enhancement of invasion[111]
	CCL20	Upregulated with bacterial infection in OSCC cell lines[152]
Esophagus	CXCL8	Possible index of inflammation, upregulation in cancer-related cachexia[113,114]
	CXCR4	Positive regulator of HER[116]
Stomach	CXCL12, CXCR4	Metastasis through activation of AKT-mTOR pathway and MMPs, upregulation in lymph node metastasis, strong correlation with tumor development[117,118,124]
	CXCR4	Enhancement of metastasis through p38 signaling pathway[119]
	CXCL12	Acquisition of invasive/metastatic phenotype, enhancement of proliferation when coexpressed with other molecules[120,123]
	CXCL1	Activation of lymphangiogenesis by stimulating LECs[126]
	CXCR2	Strong correlation with TNM staging and lymphatic vessel density[127-130]
	CXCL8	Enhancement of tumor development factors, and a possible risk factor as mutant, association with angiogenesis, development of gastric adenocarcinoma[132-134,183]
	CXCL5	Marker for late stage gastric cancer[137]
	Other candidates	CC-chemokines (CCL2, 3, 5, 21, 25)/CXC-chemokines (1, 7, 8, 12, 14)/CCR6[139]
Liver	CXCR4	Metastasis, upregulation in PVTT[142-143]
	CXCR2	Upregulation in HCC, especially in late stage[128]
	CCL2	Application to prevent metastasis, application to prevent HCC by deactivating AKT pathway[144-147]
	CXCR7	Upregulation in HCC, functional in tumor development and angiogenesis but not in metastasis[148-149]
	CXCL12, CXCR4	Enhancement of tumor cell extravasation through upregulation of Rho/Rac/Cdc42[150]
	CCR6	Upregulation in metastasis[153]
	CCL20	Enhanced expression in HCC[155]
	D6 receptor	Prevention of liver injury[171]
Pancreas	CCL20	Associated with tumor staging[154]
	CCR6	Upregulated in chronic pancreatitis, pancreatic cystadenoma and pancreatic carcinoma[154]
	CXCL5, CXCL8	Upregulation in metastatic pancreatic carcinoma[140]
	CXCL5	Correlated with poorer tumor differentiation, advanced clinical stage, and shorter patient survival, and ERK, AKT and STAT mediated angiogenesis[156]
	CXCL8, CXCR1/2	Upregulation in adenocarcinomas and neuroendocrine tumors[157]
	CXCL12, CXCR4	Downregulation of CXCL12 and upregulation of CXCR4 in tumors. CXCL12 correlated with MVD but not with MLVD, while CXCR4 showed opposite pattern[158]
	CXCR4, CXCR7	CXCR7 associated with tumor grade, inversely associated with tumor size, and possibly associated with tumor progression and differentiation but not with CXCR4[159]
	CX3CL1,CX3CR1	Perineural invasion and dissemination of neoplastic cells along intra- and extra-pancreatic nerves[163,164]
	CXCL17 (+ ICAM2)	Diagnostic molecular marker[167]
	CXCL7 (+ CA19-9)	Diagnostic molecular marker[168]
Colon	CXCL4L1	Upregulation in colorectal cancer[115]
	CCL2	upregulation in mucosa of IBD[169]
	D6 receptor	Plays role of sequestering several chemokines (in mouse colitis model experiment), plays suppressive role in the development and growth of vascular tumors[170,172]
	CCL2, CCR2	important mediator in colon tumor development[173]
	CXCL8	Upregulation along with the development of Crohn's disease, affecting biological responses of human intestinal microvascular endothelial cells in colitis model, positvely correlated with earlier disease stage and improved relapse-free survival[164,175,180]
	CXCL10, CXCL41	Synergistic upregulation with CXCL8 by diverse stimuli, induction by ERK2 and PI-3K/AKT pathway via PAR2[175,178]
	CCL20, CXCL1/2, CXCL8	Remains high even after the treatment with anti-TNF antibody[179]
	CXCL1, CXCR1/2	Upregulation in stage II and III CRC, upregulation in stage II and III CRC[180]
	CXCR3 pathway	CXCL9-pediatric Crohn’s disease, CXCL11-UC in all age groups[181]
	Other chemokines	IL-17 affects CXCL8, CXCL1, CCL20, CXCL10, CXCL11 and CCR5 in colon cancer cells[182]

CXCL: CXC chemokine ligand; CXCR: CXC-chemokine receptor; CCR: CC-receptor; CX₃CR: CX₃C-receptor; CA19-9: Carbohydrate antigen 19-9; OSCC: Oral squamous cell carcinoma; HER: Human epidermal growth factor receptor; AKT: Protein kinase B; mTOR: Mammalian target of rapamycin; MMPs: Matrix metalloproteinases; LECs: Lymphatic endothelial cells; TNM: Tumor, node, and metastasis; PVTT: Portal vein tumor thrombus; HCC: Hepatocellular carcinoma; STAT: Signal transducer and activator of transcription; ERK: Extracellular signal-regulated kinase; MVD: Microvessel density; MLVD: Microlymphatic vessel density; IBD: Inflammatory bowel disease; PI-3K: Phosphatidyl inositide-3-OH kinase; PAR2: Protease-activated receptor-2; CRC: Colorectal cancer; IL: Interleukin; TNF-α: Tumor necrosis factor-α.

CHEMOKINE NETWORK AS A THERAPEUTIC TARGET

With the recent advances in understanding of the many and varied roles of chemokines and their receptors in tumor development and progression, together with the advent of targeted molecular therapies, excellent opportunities exist to develop novel approaches to treat cancer. This would appear to be of particular relevance for gastrointestinal malignancies, where radical improvements in clinical outcome have so far been elusive.

CONCLUSION

It is clear that chemokine networks play critical roles in inflammatory diseases and cancer progression, and tumor cells may influence their own proliferation as well as affecting stromal and immune system cells, and vice versa. Therefore, the chemokine network makes an attractive target for therapeutic intervention in many tumor types, including those of the gastrointestinal tract. However, we need to define more selective and specific targets, to minimize systemic side effects during treatment.